LINC00208: A Potential Drug Target Or Biomarker for Cancer (G83655)

Target Name: LINC00208

NCBI ID: G83655

LINC00208

Other Name(s): C8orf14 | Long intergenic non-protein coding RNA 208 | VIR35 | NCRNA00208 | long intergenic non-protein coding RNA 208

LINC00208: A Potential Drug Target Or Biomarker for Cancer

LINC00208 (C8orf14) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 8 and has been shown to play a role in the development and progression of several diseases, including cancer.

Research has shown that LINC00208 is involved in the regulation of various cellular processes, including cell growth, apoptosis (programmed cell death), and inflammation. It has also been shown to be involved in the development and progression of various diseases, including cancer.

One of the most promising aspects of LINC00208 is its potential as a drug target. By blocking the activity of LINC00208, researchers can reduce the growth and spread of cancer cells, which could lead to a more effective treatment of the disease.

In addition to its potential as a drug target, LINC00208 has also been shown to be a potential biomarker for the diagnosis and prognosis of various diseases, including cancer. By analyzing the expression of LINC00208 in cancer cells and cancer tissues, researchers can gain insights into the effectiveness of different treatments and monitor the progress of the disease.

Overall, LINC00208 is a promising gene that has the potential to be a drug target or biomarker for the treatment of various diseases, including cancer. Further research is needed to fully understand its role and potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 208

The "LINC00208 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00208 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets